Kevzara

Active Ingredient(s): Sarilumab
FDA Approved: * May 22, 2017
Pharm Company: * SANOFI SYNTHELABO
Category: Arthritis

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Kevzara Overview

Sarilumab (trade name Kevzara) is a human monoclonal antibody against the interleukin-6 receptor.[1] Regeneron Pharmaceuticals and Sanofi developed the drug for the treatment of rheumatoid arthritis (RA), for which it received US FDA approval on 22 May 2017 and European Medicines Agency approval on 23 June 2017.[2] Development in ankylosing spondylitis has been suspended after the drug failed to show clinical benefit over methotrexate in a phase II trial.&#...

Read more Kevzara Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Sarilumab

Recent Kevzara Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Sarilumab

Injection: 150mg/1.14ml, 200mg/1.14ml

Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Kevzara: (4 results)

Sorted by National Drug Code

0024-5908 Kevzara 150 mg/1.14ml Subcutaneous Injection, Solution by Sanofi-aventis U.S. LLC
0024-5910 Kevzara 200 mg/1.14ml Subcutaneous Injection, Solution by Sanofi-aventis U.S. LLC
0024-5920 Kevzara 150 mg/1.14ml Subcutaneous Injection, Solution by Sanofi-aventis U.S. LLC
0024-5922 Kevzara 200 mg/1.14ml Subcutaneous Injection, Solution by Sanofi-aventis U.S. LLC

Other drugs which contain Sarilumab or a similar ingredient: (1 result)

SARILUMAB